New York State Common Retirement Fund
VKTX icon

New York State Common Retirement Fund’s Viking Therapeutics VKTX Stock Holding History

New York State Common Retirement Fund’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
57,863
+5,900
+11% +$191K ﹤0.01% 1422
2026
Q1 		$1.69M Hold
51,963
– – ﹤0.01% 1450
2025
Q4 		$1.83M Sell
51,963
-60,735
-54% -$2.15M ﹤0.01% 1441
2025
Q3 		$2.96M Sell
112,698
-6,200
-5% -$185K ﹤0.01% 1293
2025
Q2 		$3.15M Hold
118,898
– – ﹤0.01% 1249
2025
Q1 		$2.87M Hold
118,898
– – ﹤0.01% 1260
2024
Q4 		$4.78M Sell
118,898
-3,500
-3% -$200K 0.01% 1122
2024
Q3 		$7.75M Buy
122,398
+63,335
+107% +$3.72M 0.01% 903
2024
Q2 		$3.13M Buy
59,063
+2,751
+5% +$180K ﹤0.01% 1306
2024
Q1 		$4.62M Buy
56,312
+16,991
+43% +$756K 0.01% 1150
2023
Q4 		$732K Buy
39,321
+609
+2% +$7.96K ﹤0.01% 1939
2023
Q3 		$429K Sell
38,712
-2,326
-6% -$33.3K ﹤0.01% 2121
2023
Q2 		$665K Sell
41,038
-58,147
-59% -$1.22M ﹤0.01% 1950
2023
Q1 		$1.65M Buy
+99,185
New +$1.02M ﹤0.01% 1634
2022
Q3 		– Sell
-452
Closed -$1K – 3455
2022
Q2 		$1K Sell
452
-58,652
-99% -$145K ﹤0.01% 3418
2022
Q1 		$177K Buy
59,104
+22,828
+63% +$81.9K ﹤0.01% 2859
2021
Q4 		$167K Sell
36,276
-250,897
-87% -$1.41M ﹤0.01% 2935
2021
Q3 		$1.8M Sell
287,173
-14,969
-5% -$92.5K ﹤0.01% 1813
2021
Q2 		$1.81M Buy
302,142
+545
+0.2% +$3.24K ﹤0.01% 1930
2021
Q1 		$1.91M Hold
301,597
– – ﹤0.01% 1804
2020
Q4 		$1.7M Hold
301,597
– – ﹤0.01% 1765
2020
Q3 		$1.75M Hold
301,597
– – ﹤0.01% 1639
2020
Q2 		$2.17M Hold
301,597
– – ﹤0.01% 1491
2020
Q1 		$1.41M Hold
301,597
– – ﹤0.01% 1570
2019
Q4 		$2.42M Sell
301,597
-15,700
-5% -$114K ﹤0.01% 1547
2019
Q3 		$2.18M Sell
317,297
-29,792
-9% -$221K ﹤0.01% 1604
2019
Q2 		$2.88M Buy
347,089
+16,000
+5% +$137K ﹤0.01% 1476
2019
Q1 		$3.29M Sell
331,089
-5,288
-2% -$44.3K ﹤0.01% 1397
2018
Q4 		$2.57M Buy
336,377
+243,897
+264% +$2.92M ﹤0.01% 1441
2018
Q3 		$1.61M Buy
92,480
+19,655
+27% +$234K ﹤0.01% 1816
2018
Q2 		$691K Buy
+72,825
New +$484K ﹤0.01% 2308

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

New York State Common Retirement Fund's VKTX Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Viking Therapeutics (VKTX) stake by 11% in Q2 2026, buying an estimated $191K and bringing the position to 57,863 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1422.

New York State Common Retirement Fund first reported a position in VKTX in Q2 2018 and has held it in 31 quarters since. The position peaked at $7.75M in Q3 2024. 195 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • New York State Common Retirement Fund held 57,863 shares of Viking Therapeutics worth $2.26M as of Q2 2026.
  • New York State Common Retirement Fund bought 5,900 Viking Therapeutics shares in Q2 2026, an estimated $191K.
  • Viking Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1422 holding.
  • New York State Common Retirement Fund first reported a position in Viking Therapeutics in Q2 2018 and has held it in 31 quarters since.
  • New York State Common Retirement Fund's Viking Therapeutics position peaked at $7.75M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.